Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin
- PMID: 11739166
- DOI: 10.1182/blood.v98.13.3626
Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin
Abstract
Erythropoietin (EPO) from sera obtained from anemic patients was successfully isolated using magnetic beads coated with a human EPO (hEPO)-specific antibody. Human serum EPO emerged as a broad band after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with an apparent molecular weight slightly smaller than that of recombinant hEPO (rhEPO). The bandwidth corresponded with microheterogeneity because of extensive glycosylation. Two-dimensional gel electrophoresis revealing several different glycoforms confirmed the heterogeneity of circulating hEPO. The immobilized anti-hEPO antibody was capable of binding a representative selection of rhEPO glycoforms. This was shown by comparing normal-phase high-performance liquid chromatography profiles of oligosaccharides released from rhEPO with oligosaccharides released from rhEPO after isolation with hEPO-specific magnetic beads. Charge analysis demonstrated that human serum EPO contained only mono-, di-, and tri-acidic oligosaccharides and lacked the tetra-acidic structures present in the glycans from rhEPO. Determination of charge state after treatment of human serum EPO with Arthrobacter ureafaciens sialidase showed that the acidity of the oligosaccharide structures was caused by sialic acids. The sugar profiles of human serum EPO, describing both neutral and charged sugar, appeared significantly different from the profiles of rhEPO. The detection of glycan structural discrepancies between human serum EPO and rhEPO by sugar profiling may be significant for diagnosing pathologic conditions, maintaining pharmaceutical quality control, and establishing a direct method to detect the misuse of rhEPO in sports.
Comment in
-
Sugar in erythropoietin: clinical and forensic implications.Blood. 2002 Mar 1;99(5):1503. doi: 10.1182/blood.v99.5.1503. Blood. 2002. PMID: 11861258 No abstract available.
-
Differences between the N-glycans of human serum erythropoietin and recombinant human erythropoietin.Blood. 2003 Feb 1;101(3):1204; author reply 1204-5. doi: 10.1182/blood-2002-09-2988. Blood. 2003. PMID: 12529299 No abstract available.
Similar articles
-
Dynamic control of oligosaccharide modification in the mammary gland: linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO.Transgenic Res. 2006 Feb;15(1):37-55. doi: 10.1007/s11248-005-3519-2. Transgenic Res. 2006. PMID: 16475009
-
The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design.Drug Test Anal. 2011 Nov-Dec;3(11-12):883-91. doi: 10.1002/dta.388. Epub 2011 Dec 2. Drug Test Anal. 2011. PMID: 22140023
-
Quantitative mapping of the N-linked sialyloligosaccharides of recombinant erythropoietin: combination of direct high-performance anion-exchange chromatography and 2-aminopyridine derivatization.Anal Biochem. 1992 Nov 1;206(2):278-87. doi: 10.1016/0003-2697(92)90367-g. Anal Biochem. 1992. PMID: 1443598
-
The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.Eur J Haematol. 2002 Nov-Dec;69(5-6):265-74. doi: 10.1034/j.1600-0609.2002.02813.x. Eur J Haematol. 2002. PMID: 12460230 Review.
-
Recent Progress in the Synthesis of Homogeneous Erythropoietin (EPO) Glycoforms.Chembiochem. 2020 Dec 1;21(23):3301-3312. doi: 10.1002/cbic.202000347. Epub 2020 Jul 30. Chembiochem. 2020. PMID: 33210450 Review.
Cited by
-
Survival and proliferative roles of erythropoietin beyond the erythroid lineage.Expert Rev Mol Med. 2008 Dec 1;10:e36. doi: 10.1017/S1462399408000860. Expert Rev Mol Med. 2008. PMID: 19040789 Free PMC article. Review.
-
Dynamic control of oligosaccharide modification in the mammary gland: linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO.Transgenic Res. 2006 Feb;15(1):37-55. doi: 10.1007/s11248-005-3519-2. Transgenic Res. 2006. PMID: 16475009
-
Satisfying QTPP of Erythropoietin Biosimilar by QbD through DoE-Derived Downstream Process Engineering.Pharmaceutics. 2023 Aug 4;15(8):2087. doi: 10.3390/pharmaceutics15082087. Pharmaceutics. 2023. PMID: 37631301 Free PMC article.
-
Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.Drugs. 2004;64(5):499-509. doi: 10.2165/00003495-200464050-00004. Drugs. 2004. PMID: 14977387 Review.
-
Development and validation of a method for analyzing the sialylated glycopeptides of recombinant erythropoietin in urine using LC-HRMS.Sci Rep. 2023 Mar 8;13(1):3860. doi: 10.1038/s41598-023-31030-y. Sci Rep. 2023. PMID: 36890204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials